Latest news with #Leveragen
Associated Press
25-03-2025
- Business
- Associated Press
Leveragen Partners with Cell Signaling Technology to Advance Reagent Antibody Innovation with Proprietary Nanobody Technology
Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. This press release features multimedia. View the full release here: Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. Nanobodies, or single-domain antibodies, are only about 10% the size of traditional antibodies, yet retain high target-binding affinity, exhibit enhanced tissue penetration, and can tackle structurally-challenging targets inaccessible to some full-length antibodies. Leveragen's Singularity Suite of nanobody mice harnesses cutting-edge genetic engineering technologies to remove competing conventional antibodies and preserve native immunoglobulin gene regulation, maximizing nanobody-specific immune responses and maintaining normal B-cell development. Similar to its flagship Singularity Sapiens platform of fully human single-domain antibodies developed for therapeutic applications, the Singularity Musculus platform is purpose-built to generate mouse-derived nanobodies with superior diversity, affinity, stability, and cost-efficiency—traits critical to developing high-performance reagents for research and diagnostic applications. 'We are excited to begin this partnership with CST, marking a major milestone that underscores our commitment to antibody innovation,' said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen Inc. 'Our Singularity Musculus platform was developed specifically to meet the growing need for versatile, diverse, and reproducible reagent antibodies. By merging our proprietary Singularity Musculus platform with CST's renowned expertise in antibody reagents, we aim to raise the bar for nanobody-based tools throughout the life sciences.' Dr. Roberto Polakiewicz, Chief Scientific Officer at Cell Signaling Technology, commented, 'We are delighted to collaborate with Leveragen to explore the Singularity Musculus platform and its potential to advance reagent antibody development for researchers around the world.' This partnership highlights the growing significance of nanobody-based technologies in areas including basic research, diagnostics, and therapeutic development. With their small molecular footprint, modular monomeric structure, robust binding affinity, and suitability for certain challenging antigens, nanobodies are uniquely positioned for high-throughput screening, precision imaging, and other advanced life science applications. By combining Leveragen's and CST's expertise, the collaboration aims to accelerate the creation of next-generation reagent antibodies. About Leveragen Leveragen is a genetic engineering company dedicated to transforming antibody discovery and development for research, diagnostics, and therapeutics. Operating exclusively from its Woburn, Massachusetts facility, the company employs advanced genome editing, synthetic biology, and chromosomal engineering technologies to develop next-generation genetic models that accelerate antibody discovery. Leveragen's proprietary collection of nanobody mice, the Singularity Suite, features Singularity Sapiens, designed to generate fully human single-domain antibodies for developing a broad range of biologic modalities, and Singularity Musculus, engineered to produce mouse-derived single-domain antibodies optimized for high-performance reagent applications. Through strategic collaborations with global pharmaceutical and biotechnology leaders, the company addresses unmet medical needs and accelerates the translation of scientific breakthroughs into practical solutions. For more information, please visit About Cell Signaling Technology Cell Signaling Technology (CST), headquartered in Danvers, Massachusetts, is a global leader in the development and production of high-quality research antibodies, reagents, and related technologies. Established in 1999 by scientists committed to furthering cellular and molecular research, CST has earned a reputation for excellence through rigorous validation processes, innovative products, and dedication to reproducibility. Serving academia, pharmaceuticals, and biotechnology worldwide, CST provides tools that help researchers investigate complex signaling pathways, uncover disease mechanisms, and accelerate therapeutic discovery. With a focus on quality and customer service, CST remains at the cutting edge of life science innovation. Learn more at SOURCE: Leveragen Inc. Copyright Business Wire 2025. PUB: 03/25/2025 08:08 AM/DISC: 03/25/2025 08:08 AM
Yahoo
25-03-2025
- Business
- Yahoo
Leveragen Partners with Cell Signaling Technology to Advance Reagent Antibody Innovation with Proprietary Nanobody Technology
BOSTON, March 25, 2025--(BUSINESS WIRE)--Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. Nanobodies, or single-domain antibodies, are only about 10% the size of traditional antibodies, yet retain high target-binding affinity, exhibit enhanced tissue penetration, and can tackle structurally-challenging targets inaccessible to some full-length antibodies. Leveragen's Singularity Suite of nanobody mice harnesses cutting-edge genetic engineering technologies to remove competing conventional antibodies and preserve native immunoglobulin gene regulation, maximizing nanobody-specific immune responses and maintaining normal B-cell development. Similar to its flagship Singularity Sapiens platform of fully human single-domain antibodies developed for therapeutic applications, the Singularity Musculus platform is purpose-built to generate mouse-derived nanobodies with superior diversity, affinity, stability, and cost-efficiency—traits critical to developing high-performance reagents for research and diagnostic applications. "We are excited to begin this partnership with CST, marking a major milestone that underscores our commitment to antibody innovation," said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen Inc. "Our Singularity Musculus platform was developed specifically to meet the growing need for versatile, diverse, and reproducible reagent antibodies. By merging our proprietary Singularity Musculus platform with CST's renowned expertise in antibody reagents, we aim to raise the bar for nanobody-based tools throughout the life sciences." Dr. Roberto Polakiewicz, Chief Scientific Officer at Cell Signaling Technology, commented, "We are delighted to collaborate with Leveragen to explore the Singularity Musculus platform and its potential to advance reagent antibody development for researchers around the world." This partnership highlights the growing significance of nanobody-based technologies in areas including basic research, diagnostics, and therapeutic development. With their small molecular footprint, modular monomeric structure, robust binding affinity, and suitability for certain challenging antigens, nanobodies are uniquely positioned for high-throughput screening, precision imaging, and other advanced life science applications. By combining Leveragen's and CST's expertise, the collaboration aims to accelerate the creation of next-generation reagent antibodies. About Leveragen Leveragen is a genetic engineering company dedicated to transforming antibody discovery and development for research, diagnostics, and therapeutics. Operating exclusively from its Woburn, Massachusetts facility, the company employs advanced genome editing, synthetic biology, and chromosomal engineering technologies to develop next-generation genetic models that accelerate antibody discovery. Leveragen's proprietary collection of nanobody mice, the Singularity Suite, features Singularity Sapiens, designed to generate fully human single-domain antibodies for developing a broad range of biologic modalities, and Singularity Musculus, engineered to produce mouse-derived single-domain antibodies optimized for high-performance reagent applications. Through strategic collaborations with global pharmaceutical and biotechnology leaders, the company addresses unmet medical needs and accelerates the translation of scientific breakthroughs into practical solutions. For more information, please visit About Cell Signaling Technology Cell Signaling Technology (CST), headquartered in Danvers, Massachusetts, is a global leader in the development and production of high-quality research antibodies, reagents, and related technologies. Established in 1999 by scientists committed to furthering cellular and molecular research, CST has earned a reputation for excellence through rigorous validation processes, innovative products, and dedication to reproducibility. Serving academia, pharmaceuticals, and biotechnology worldwide, CST provides tools that help researchers investigate complex signaling pathways, uncover disease mechanisms, and accelerate therapeutic discovery. With a focus on quality and customer service, CST remains at the cutting edge of life science innovation. Learn more at View source version on Contacts Media Contact Leveragen Media RelationsEmail: media@ Sign in to access your portfolio
Associated Press
29-01-2025
- Business
- Associated Press
Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies Using Proprietary Fully Human Single-Domain Antibody Technology
WOBURN, Mass.--(BUSINESS WIRE)--Jan 29, 2025-- Leveragen Inc., a Boston-based biotech company specializing in next-generation genetic models for antibody discovery, today announced a strategic collaboration with Moonlight Bio, a Seattle-based biotech company pioneering advanced T cell therapies. This partnership aims to develop cutting-edge T cell therapies to address some of the most challenging and difficult-to-treat cancers. This press release features multimedia. View the full release here: Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies. The collaboration integrates Leveragen's proprietary Singularity Sapiens Mouse platform, a groundbreaking tool for generating fully human single-domain antibodies, with Moonlight Bio's expertise in T cell engineering. Together, the two companies seek to create T cell therapies with enhanced functionality, persistence, and efficacy, overcoming significant barriers in the treatment of solid tumors. (Graphic: Business Wire) The collaboration integrates Leveragen's proprietary Singularity Sapiens Mouse platform, a groundbreaking tool for generating fully human single-domain antibodies, with Moonlight Bio's expertise in T cell engineering. Together, the two companies seek to create T cell therapies with enhanced functionality, persistence, and efficacy, overcoming significant barriers in the treatment of solid tumors. 'Leveragen's mission is to drive innovation in the fight against life-threatening diseases, and expanding our fully human single-domain antibody technology into transformative T cell therapies aligns seamlessly with this vision,' said Weisheng Chen, Founder and CEO of Leveragen. 'Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.' 'At Moonlight Bio, we are dedicated to delivering T cell therapies that break through barriers obstructing successful outcomes in solid tumors – the vast majority of the global cancer disease burden,' said Jordan Jarjour, Moonlight Bio's CSO. 'Leveragen's Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T cell therapies, particularly when combined with the tools and technologies that the Moonlight Bio team is advancing. We are very excited to collaborate with Leveragen as we explore and create new solutions in this space.' Under the terms of the agreement, Leveragen will spearhead the discovery of fully human single-domain antibodies against therapeutic targets and Moonlight Bio will oversee the preclinical development of T cell therapies. This collaboration highlights Leveragen's leadership in single-domain antibody discovery and its commitment to advancing immunotherapy through innovative science and transformative applications. About Leveragen Leveragen is a genetic engineering company at the forefront of developing next-generation models for antibody discovery and biologics innovation. Leveragen's flagship platform, the Singularity Sapiens Mouse, is designed to produce heavy chain-only antibodies from the entire human VH repertoire precisely integrated into the mouse genome. By eliminating conventional antibody interference and faithfully replicating human immunoglobulin gene expression, the platform optimizes B cell development and generates robust immune responses, enabling the efficient derivation of fully human single-domain antibodies with unsurpassed diversity, affinity, and developability. This proprietary platform accelerates the discovery and development of diverse therapeutic modalities, including bispecifics, ADCs, CAR T, and mRNA-based treatments. Headquartered in Woburn, Massachusetts, Leveragen collaborates with global pharmaceutical and biotechnology leaders to drive next-generation therapeutic development. For more information, visit About Moonlight Bio Moonlight Bio, Inc. is a preclinical-stage biotechnology company based in Seattle, WA aiming to develop potency enhanced T cell therapies that provide new hope for patients suffering from cancer. Moonlight's core technologies were illuminated by nature itself and are designed to confront the disappointing reality that therapies for solid tumors are simply not potent enough to generate the deep and durable responses that patients urgently need. To learn more, connect with Moonlight Bio on LinkedIn and visit us at SOURCE: Leveragen Inc. Copyright Business Wire 2025. PUB: 01/29/2025 08:08 AM/DISC: 01/29/2025 08:08 AM
